BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma-Reference-Cited by-同舟云学术

BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma

Published:2015-01-22 Issue:4 Volume:125 Page:658-667
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Correia Cristina¹,Schneider Paula A.¹,Dai Haiming¹,Dogan Ahmet²,Maurer Matthew J.³,Church Amy K.⁴,Novak Anne J.⁴,Feldman Andrew L.²,Wu Xiaosheng⁵,Ding Husheng¹,Meng X. Wei¹,Cerhan James R.⁶,Slager Susan L.³,Macon William R.²,Habermann Thomas M.⁴,Karp Judith E.⁷,Gore Steven D.⁷,Kay Neil E.⁴,Jelinek Diane F.⁴⁵,Witzig Thomas E.⁴,Nowakowski Grzegorz S.⁴,Kaufmann Scott H.¹⁴

Affiliation:

1. Division of Oncology Research, Department of Oncology,

2. Division of Hematopathology, Department of Laboratory Medicine and Pathology,

3. Division of Biomedical Statistics and Bioinformatics, Department of Health Sciences Research,

4. Division of Hematology, Department of Medicine,

5. Department of Immunology, and

6. Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN; and

7. Division of Hematological Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD

Abstract

Key Points BCL2 mutations in FL correlate with activation-induced cytidine deaminase expression and frequently alter the amino acid sequence of the protein. Mutations in the BCL2 coding sequence at diagnosis are associated with shortened time to transformation and earlier death due to lymphoma.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/125/4/658/1387296/658.pdf

Reference61 articles.

1. Management of indolent lymphoma: where are we now and where are we going.;Lunning;Blood Rev,2012

2. Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation.;Sehn;Biol Blood Marrow Transplant,2012

3. The optimal management of follicular lymphoma: an evolving field.;Ujjani;Drugs,2013

4. Histologic progression in non-Hodgkin’s lymphoma.;Hubbard;Blood,1982

5. Histologic conversion in the non-Hodgkin’s lymphomas.;Acker;J Clin Oncol,1983

Cited by 115 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphoma;Blood Advances;2024-07-29

2. PAQR4 oncogene: a novel target for cancer therapy;Medical Oncology;2024-05-20

3. Phenotyping of cancer-associated somatic mutations in the BCL2 transmembrane domain;Oncogenesis;2024-04-26

4. Analyzing the risk factors for disease progression within 2 years and histological transformation in patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone as first‐line treatment: A 15‐year follow‐up of patients with advanced follicular lymphoma in JCOG0203;Hematological Oncology;2024-04-10

5. BCL2 Protein Progressively Declines during Robust CLL Clonal Expansion: Potential Impact on Venetoclax Clinical Efficacy and Insights on Mechanism;Lymphatics;2024-03-28